Apimeds Pharmaceuticals US (APUS) Accumulated Expenses (2023 - 2026)

Apimeds Pharmaceuticals US (APUS) has reported Accumulated Expenses for 4 consecutive years, with $3.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Accumulated Expenses changed N/A year-over-year to $3.2 million; the trailing twelve-month figure through Jun 2026 stood at $3.2 million (changed N/A YoY), and the FY2025 full-year result was $918649.0, up 55.39% from the prior year.
• Accumulated Expenses grew to $3.2 million in Q2 2026 per APUS's latest filing, from $918649.0 in the prior quarter.
• Across five years, Accumulated Expenses topped out at $3.2 million in Q2 2026 and bottomed at $68878.0 in Q4 2023.
• Historically, Accumulated Expenses has averaged $983652.0 across 4 years, with a median of $591191.0 in 2024.
• The sharpest annual moves came in 2024 and 2025: Accumulated Expenses jumped 758.32% in 2024, then soared 55.39% in 2025.
• Over 4 years, Accumulated Expenses stood at $68878.0 in 2023, then surged by 758.32% to $591191.0 in 2024, then jumped by 55.39% to $918649.0 in 2025, then surged by 250.69% to $3.2 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $3.2 million, $918649.0, and $117899.0 for Q2 2026, Q4 2025, and Q1 2025 respectively.